Stealth BioTherapeutics says agency decision on Barth syndrome therapy may not come for up to six monthsIn the latest twist over the fate of an ultra-rare disease drug, Stealth BioTherapeutics said it received “conflicting” signals from the U.S. Food and Drug Administration about information needed to approve its therapy and, consequently, is making contingency plans […]
